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Wild-type KRAS (KRASWT) amplification has been shown to be a secondary means of KRAS
activation in cancer and associated with poor survival. Nevertheless, the precise role of
KRASWT overexpression in lung cancer progression is largely unexplored. Here, we identify
and characterize a KRAS-responsive lncRNA, KIMAT1 (ENSG00000228709) and show that
it correlates with KRAS levels both in cell lines and in lung cancer specimens. Mechanistically,
KIMAT1 is a MYC target and drives lung tumorigenesis by promoting the processing of
oncogenic microRNAs (miRNAs) through DHX9 and NPM1 stabilization while halting the
biogenesis of miRNAs with tumor suppressor function via MYC-dependent silencing of p21, a
component of the Microprocessor Complex. KIMAT1 knockdown suppresses not only KRAS
expression but also KRAS downstream signaling, thereby arresting lung cancer growth
in vitro and in vivo. Taken together, this study uncovers a role for KIMAT1 in maintaining a
positive feedback loop that sustains KRAS signaling during lung cancer progression and
provides a proof of principle that interfering with KIMAT1 could be a strategy to hamper
KRAS-induced tumorigenesis.
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While drugs that inhibit KRAS for therapeutic gain beginto be available in the clinic for patients with specificKRAS mutations1, the functional role of KRASWT
amplification, which has recently been shown to be a secondary
means of KRAS activation in cancer2, remains mostly unexplored.
The largest part of the human genome is composed of non-
coding genes, which are transcribed but not translated into pro-
teins, defined as non-coding RNAs. The most abundant class of
these non-coding transcripts in mammals is represented by long
non-coding RNAs (lncRNAs), RNAs molecules longer than 200
nucleotides which affect gene expression through interaction with
DNA, RNA or proteins3. High-throughput RNA sequencing
studies have led to the identification of lncRNAs with oncogenic
or tumor suppressive properties in many cancer types, including
lung cancer4–6. Although lncRNAs are clearly a crucial layer of
biological regulation, only a few have been functionally char-
acterized and the molecular mechanism(s) behind their biology
remains largely unknown.
Another class of regulatory non-coding RNAs, miRNAs, have
gained significant importance in the past decades as master reg-
ulators of gene expression7. MiRNAs bind to the 3’UTR of target
genes inhibiting their translation or inducing mRNA degradation.
MiRNA biogenesis is a complex process in which the primary
transcripts of miRNA genes (pri-miRNAs) are cleaved in the
nucleus into precursor miRNAs (pre-miRNAs) by the Micro-
processor Complex (MC), essentially composed of the RNase III
DROSHA, DGCR8 and RNA associated proteins including p68
(DDX5) and p72 (DDX17)8–10. Pre-miRNAs are further pro-
cessed in the cytoplasm into mature miRNAs by Dicer, another
RNase III related enzyme. MiRNA dysregulation is a hallmark of
human cancers and miRNA roles as tumor promoters (TP) or
tumor suppressors (TS) have been validated in several studies to
date11. Here, we leverage the pleiotropic functions of lncRNAs to
potentially identify pathways regulated by KRAS that could be
exploited for therapeutic purpose. We characterize a human
KRAS-responsive lncRNA, KIMAT1, which sustains essential
oncogenic signaling by modulating components of the MC and
miRNA biogenesis, thereby promoting lung cancer progression.
We have therefore, uncovered a function for a lncRNA in
miRNA processing, which may shed light on key aspects of
cancer biology.
Results
Identification of KRAS-responsive lncRNAs. Through in silico
analysis of KRAS copy number alteration (CNA) in human
clinical samples from the Cancer Genome Atlas (TCGA), we
identified high level amplification of the KRAS gene, as pre-
viously reported12, as well KRAS copy number gain (see meth-
ods) in both lung adenocarcinoma (LUAD) and lung squamous
cell carcinoma (LUSC), with consequent increase of KRAS
mRNA (Fig. 1a and Supplementary Fig. 1a). 17% of LUAD
patients with KRAS gain/amplification also harbored a mutant
KRAS allele (Supplementary Data 1). Kaplan–Meier survival
analysis revealed that patients with amplified KRAS had a poorer
disease-free survival compared to patients with nonamplified
KRAS status (Fig. 1b). To identify potential KRAS-modulated
pathways we searched for KRAS-responsive lncRNAs. We car-
ried out RNA sequencing (RNA-seq) analysis after over-
expression (OE) of either KRASWT or KRASG12D in H1299 cells,
which although harboring an NRAS mutation do not depend on
NRAS signaling13. Setting a threshold fold change (FC) > 1.5 or
<0.8 and padj < 0.05, a total of 1783 protein-coding genes and
104 lncRNAs were concordantly induced or repressed by
KRASWT or KRASG12D (Supplementary Fig. 1b) (raw data
accessible via GSE124631), suggesting that a substantial portion
of the KRAS signaling remains uncharacterized. Gene set
enrichment analysis (GSEA) revealed that “MYC targets”,
“angiogenesis” and “epithelial to mesenchymal transition
(EMT)” signatures were significantly induced in the KRAS
associated genes (Supplementary Fig. 1c and Supplementary
Data 2). The top-scored lncRNAs induced by KRAS, with a fold
change above 3, were Linc02575 and HIF1A-As2 (Fig. 1c). While
HIF1A-as2 has been previously reported to have an oncogenic
role in different tumor types14,15, Linc02575 has never been
characterized before. Thus, in this study we focused on
Linc02575, thereafter referred as KIMAT1 (KRAS-Induced-
Metastasis-Associated-Transcript 1). KIMAT1 is a long inter-
genic non-coding RNA located on chromosome 21 with only one
isoform (Supplementary Fig. 1d). KIMAT1’s transcript full
length (912 nt) was determined by a rapid amplification of
cDNA ends (RACE) (Supplementary Fig. 1e). KIMAT1 is not
conserved in other species (Supplementary Fig. 1f) and its sec-
ondary structure is shown in Supplementary Fig. 1g. Coding
Potential Assessment Tool (CPAT)16 with KRAS and MALAT1
as controls, was used to validate that KIMAT1 is a non-coding
transcript (Supplementary Fig. 1h). We next verified regulation
of KIMAT1 by KRASWT or KRASG12D in multiple cell lines,
including the normal immortalized BEAS2B cells which harbor
KRASWT, confirming that KRAS OE increased whilst KRAS
silencing decreased KIMAT1 expression (Supplementary
Fig. 1i–k). Additionally, silencing or inhibition of molecules
upstream or downstream of KRAS led to KIMAT1 down-
regulation (Supplementary Fig. 1l, m). To decipher the con-
tribution of KIMAT1 in KRAS-induced tumorigenesis, we
generated BEAS2B and H1299 cells stably overexpressing
KRASWT. In both cell lines KRASWT OE increased cell pro-
liferation and 3D cell invasion with a rescue of the phenotype
upon KIMAT1 knockdown (KD), evidencing that KIMAT1 is a
crucial mediator of KRAS-induced tumorigenesis (Supplemen-
tary Fig. 2a–d). Next, to verify whether KIMAT1 could be
clinically relevant, we identified genes that were both upregulated
upon KRAS OE in H1299 cells and in the LUAD and LUSC
datasets from the TCGA compared to normal lung tissues.
Interestingly, KRAS was among the most differentially expressed
protein-coding genes, whilst KIMAT1 was among the top
expressed KRAS-modulated lncRNAs in lung cancer specimens
(Fig. 1d). In situ analysis of two additional independent cohorts
confirmed that adenocarcinoma and squamous cell carcinoma
lesions expressed higher levels of KRAS and KIMAT1 compared
to the corresponding normal counterpart with a strong positive
correlation (Fig. 1e, f and Supplementary Fig. 3a–c). Notably,
there was a significant increase in KRAS and KIMAT1 expression
in late stage compared to early stage adenocarcinoma lesions,
suggesting that KIMAT1 expression increased progressively in
proportion to KRAS levels (Fig. 1e and Supplementary Fig. 3d).
KIMAT1 was also overexpressed in cells with high KRAS copy
number (Supplementary Fig. 3e), confirming a direct correlation
between KIMAT1 and KRAS also in vitro. In support of an
oncogenic role, we detected KIMAT1 expression in several other
tumor types and cancer cell lines with low or no expression in
normal tissues (Supplementary Fig. 3f).
KIMAT1 originates from Transposable Elements (TEs) and
is activated by MYC. To understand the KIMAT1 mechanism of
regulation we first identified the 5’ Transcription Starting
Site (TSS) by Cap Analysis of Gene Expression sequencing
(CAGE-seq) (Fig. 2a). In-house ChIP-seq data from H1299
cells revealed peaks of H3K4me3 and H3K27ac at the KIMAT1
promoter region, underlying the presence of an active promoter
and “open chromatin” (Fig. 2b). Then, we used JASPAR
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(http://jaspar.genereg.net), an open-access database of matrix-
based nucleotide profiles, to determine binding preference of
transcription factors17. This analysis identified binding sites for
MYC, fundamental in KRAS-induced transformation, in the
KIMAT1 promoter18. Previously published ChIP-seq data from
A549 cells revealed increased level of MYC-binding proximal to
the TSS and overlapping with H3K4me3 and H3K27ac peaks, as
expected in the case of a direct binding (Fig. 2b). Almost 50% of
the human genome sequence contains interspersed repetitive
sequences originated from mobile transposable elements (TEs),
which have been recently reported to be involved in lncRNA
origin and regulation19. TEs insert into the genome regulatory
sequences, including transcription factor binding sites20. For
instance, subfamilies of TE long terminal repeats (LTRs) harbor
functional MYC response elements responsible for transcriptional
activation20. Interestingly, inspection of the KIMAT1
promoter revealed that two MER101 LTRs, derived from endo-
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bp upstream KIMAT1 TSS contained two and one MYC BS,
respectively (Fig. 2b, c).
Furthermore, the entire KIMAT1 genomic locus was essentially
composed by remnants of ERV1 and L1 DNA in both exons and
introns. To verify whether the MER101 LTRs had potential
promoter activity, we cloned their sequences in a promoterless
pGL3 Basic vector. Dual luciferase assay revealed that the LTR
located 775 bp upstream of the TSS (MER-101-1) and containing
two MYC-binding sites (Fig. 2c), had promoter function, as the
luciferase expression increased compared to control (Fig. 2d). As
expected, MYC silencing reduced the expression of the reporter
gene fused to the MER-101-1 sequence with a rescue of the
luciferase activity upon deletion of the two MYC-binding sites. A
non-promoter region (NP) was used as negative control (Fig. 2d).
MYC binding to KIMAT1 promoter was further corroborated by
ChIP-qPCR (Fig. 2e) while MYC silencing reduced KIMAT1
expression (Fig. 2f). In a rescue experiment, MYC KD abolished
the induction of KIMAT1 by KRAS (Fig. 2g). Together, these
findings suggest that KIMAT1 is a human lncRNA originated by
evolutionary ERV1 integration events in the human genome and
transcriptionally activated by MYC.
KIMAT1 is essential for cancer cell survival, growth and
invasion. Single-molecule RNA FISH (smFISH) and subcellular
fractionation experiments indicated that KIMAT1 is localized
both in the cytoplasm and in the nucleus (Fig. 3a, b). To elucidate
KIMAT1 biological functions we designed three different LNA-
GapmeR (GpR) antisense oligonucleotides (ASOs) to silence
KIMAT1 expression (Supplementary Table 1). GpRs transfection
resulted in marked KIMAT1 KD efficiency as assessed by qPCR
and smFISH (Supplementary Fig. 4a, b). KIMAT1 silencing dra-
matically reduced cell proliferation, 3D cell invasion and clono-
genic ability in several cancer cell lines and induced remarkable
cell death (Fig. 3c–e and Supplementary Fig. 4c–e). The same
effects were observed upon KIMAT1 silencing using two inde-
pendent siRNAs (Supplementary Fig. 4f, g). Reciprocally, cells
with stable lentiviral KIMAT1 OE (Supplementary Fig. 5a)
exhibited a consistent increase in 3D cell invasion, growth in
NOD/SCID gamma (NSG) mice and long-term survival in clo-
nogenic assays (Fig. 3f–h and Supplementary Fig. 5a–c). To fur-
ther verify the specificity of the GpRs and exclude “off-targets”
effects, we deleted the region in KIMAT1 necessary for the GpRs
binding (Supplementary Fig. 5d). While, cells transfected with a
plasmid harboring KIMAT1 WT showed reduced 3D cell inva-
sion and colony formation upon GpRs transfection, cells over-
expressing mutant KIMAT1 lacking the GpR targeting site
remained unaffected, suggesting that the biological effects
observed are KIMAT1 specific (Supplementary Fig. 5e, f).
Furthermore, mutation in the GpR targeting site significantly
reduced the spheroid area in a 3D invasion assay, evidencing that
the deleted region could be a functional element in the lncRNA
sequence.
KIMAT1 interacts with DHX9 and NPM1 and is essential for
their stability. Next, to elucidate the molecular mechanisms
through which KIMAT1 could affect lung cancer progression, we
purified endogenous KIMAT1 RNA complexes by RNA antisense
purification coupled with mass spectrometry (RAP–MS)21 using
biotinylated KIMAT1 RNA antisense probes (Fig. 4a and Sup-
plementary Table 2). Forty-five proteins were reproducibly
identified in two biological replicates to interact with KIMAT1
(Supplementary Data 3). The majority of the retrieved proteins
are involved in translation, metabolism or are components of the
plasma membrane. Among the enriched proteins, two RNA-
binding proteins, DHX9 and NPM1, attracted our attention for
their roles in cancer progression22,23. RNA pull-down confirmed
the binding between KIMAT1 and DHX9, and between KIMAT1
and NPM1 (Fig. 4b and Supplementary Fig. 6a). Lysate pre-
treated with RNase A or pull down with the ubiquitin C (UBC)
probe were used as negative controls. To verify the existence of a
direct binding between KIMAT1 and DHX9 and between
KIMAT1 and NPM1, we carried out a cross-link RNA immu-
noprecipitation (CLIP) assay, which induces irreversible covalent
bonds between directly interacting proteins and RNA, as pre-
viously reported24. DHX9 or NPM1 antibody-bound complexes
exhibited a significant enrichment in KIMAT1 (Fig. 4c, d). Lnc-
CCDST and SAMD12-As1, two lncRNAs previously reported to
interact with DHX9 and NPM1, respectively, were used as posi-
tive controls25,26. Sequential immunofluorescence and smFISH
evidenced co-localization of KIMAT1/DHX9 and KIMAT1/
NPM1 in both the nucleus and cytoplasm (Fig. 4e, f). To map
KIMAT1 functional motifs that bind to DHX9 or NPM1 we
performed deletion-mapping experiments followed by in vitro
transcription and pull-down of KIMAT1 fragments. These
experiments revealed that a 399 nt region at the 5’ end of
KIMAT1 and a 258 nt region at the 3’ end of KIMAT1 are
required for the interaction with DHX9 and NPM1, respectively
(Fig. 4g). Two double-stranded RNA-binding domains (dsRBDs)
at the N-terminus of DHX9 and a DNA/RNA-binding domain
(DRBD) at the C-terminus of NPM1 (Supplementary Fig. 6b)
have been previously reported to bind nucleic acids27,28. Using
DHX9 or NPM1 deletion mutants (Supplementary Fig. 6b) fol-
lowed by CLIP assay we observed that deletion of the two DHX9
dsRBDs and the NPM1 DRBD domain abolished KIMAT1
binding (Fig. 4h, i), suggesting that these domains are essential for
the binding to KIMAT1.
Fig. 1 KRAS-responsive lncRNAs. a KRAS putative copy number alterations from GISTIC in LUAD and LUSC (TCGA), including homozygous deletions
(deep deletion, CN=−2), heterozygous deletion (shallow deletion, CN=−1), normal diploid (CN= 0), gain (CN= 1) and amplification (CN= 2 or more).
LUAD total number of patients= 513. LUSC total number of patients= 502. b, Kaplan–Meier survival curves comparing probability of disease free survival
of patients with high KRAS expression or amplified KRAS (red line) to patients with low KRAS expression or nonamplified KRAS (blue line) from the TCGA
datasets LUAD and LUSC. The log rank p values were obtained from a two-tailed Chi-Square test. c Volcano plots of significant KRAS-responsive lncRNAs
determined by RNA-seq in H1299 cells overexpressing either KRASWT or KRASG12D compared to cells transfected with an empty vector (Ev) (padj < 0.05).
d Identification of KRAS-regulated genes and lncRNAs in LUAD and LUSC lesions. Scatterplots indicate expression in LUAD and LUSC of KRAS-regulated
genes identified in Fig. 1c. The y-axis shows the log2-transformed fold change in gene expression following KRAS OE, the x-axis depicts the log2-
transformed difference in gene expression between lung adenocarcinoma (n= 540) and normal lung (GTex, n= 427) and between squamous cell
carcinoma lesions (n= 501) and normal lung (GTex, n= 427). e (Left) Representative images of KIMAT1 and KRAS in matched FFPE normal-tumor
adenocarcinoma lesions at stage 1 (T1) and stage 4 (T4) stained with DAPI (blue), KIMAT1 (pink) (smFISH) or KRAS (brown). Scale bar, 100 μm. (Right)
Quantification of KIMAT1 and KRAS expression by smFISH in tumor and normal lung tissues reported in e, Spots were counted using the online JAVA
software from StarSearch. f Direct correlation between KIMAT1 with KRAS in adenocarcinoma lesions reported in e by Pearson’s rank correlation coefficient
(r). e, f LUAD normal n= 75, T1= 37, T2a= 14, T2b= 4, T3= 16, T4= 4. Error bars indicate mean ± S.D. p values were calculated by two tailed Student’s
t test.
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Next, to determine whether deletion of DHX9 or NPM1
binding sites in KIMAT1 could abrogate its biological effects, we
cloned KIMAT1 full-length and deletion constructs in a lentiviral
vector. Overexpression of the mutants gave rise to a lower
number of colonies compared to cells transfected with KIMAT1
full length (Supplementary Fig. 6c, d), revealing that the regions
of KIMAT1 binding to DHX9 or NPM1 are important for
KIMAT1-mediated cell proliferation and corroborating previous
findings (Supplementary Fig. 5e, f). In addition, DHX9 and
NPM1 KD using siRNAs or the CRISPR/Cas9 gene-editing
system with paired single-guide RNAs (sgRNAs) decreased 3D
cell invasion, 2D and 3D cell proliferation and induced cell
death (Fig. 4j, k and Supplementary Fig. 6e–j). Notably,
KIMAT1 depletion decreased whereas KIMAT1 OE or KRAS
OE induced DHX9 and NPM1 (Fig. 4l and Supplementary
Fig. 7a, b). Therefore, KIMAT1 is important for DHX9 and
NPM1 stability and this effect is attributable to proteasomal
degradation as DHX9 and NPM1 levels were rescued upon
inhibition of the 26S proteasome complex with the proteasome
inhibitor MG132 (Supplementary Fig. 7c) and KIMAT1 silencing





























MYC binding sites (MER101-1)













191.76   
3
6.87















Chr21 (5’       3’) coordinates (Mbp)
























45.902     45.904   45.906     45.908   45.910     45.912     45.914








siCtrl + - + - + - + - + -
siMYC - + - + - + - + - +
pGL3 Basic + + - - - - - - - -
pGL3 NP - - + + - - - - - -
pGL3 MER101-1 - - - - + + - - - -
pGL3 MER101-2 - - - - - - + + - -
pGL3 MER101 Del - - - - - - - - + +
+ - + - + - + - + -
- + - + - + - + - +
+ + - - - - - - - -
- - + + - - - - - -
- - - - + + - - - -
- - - - - - + + - -
- - - - - - - - + +






























































NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22337-3 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:2038 | https://doi.org/10.1038/s41467-021-22337-3 | www.nature.com/naturecommunications 5
KIMAT1 and its interacting proteins regulate KRAS signaling.
Analysis of the TCGA datasets LUAD and LUSC and of two
independent cohorts of FFPE matched normal/tumor samples
revealed that DHX9 and NPM1 are upregulated in lung cancer
compared to normal lung and positively correlate with KRAS and
KIMAT1 (Fig. 5a, b and Supplementary Fig. 8a–c). In accordance
with a role in promoting tumor progression, high expression of
DHX9/NPM1/KIMAT1 was associated with poor overall survival
in lung cancer patients (Fig. 5c). To define the transcriptome
modulated by KIMAT1 and its interacting proteins we performed
RNA-seq in H1299 cells transfected with either KIMAT1-target-
ing GpRs or a pool of four different siRNAs targeting DHX9 or
NPM1. A total of 6278 (3732 down and 2546 up upon KIMAT1
KD), 1133 (916 down and 217 up upon DHX9 KD) and 1324
(1148 down 176 up upon NPM1 KD) (fold change >1.5 or <0.8,
padj <0.05) dysregulated genes were identified (Supplementary
Fig. 9a) (data accessible via GSE 124631). A significant overlap
between the genes modulated by KIMAT1 and DHX9 and
between the genes modulated by KIMAT1 and NPM1 was
observed (Fig. 5d). Strikingly, we noticed a significant overlap also
between genes modulated by DHX9 and NPM1 (Fig. 5d). GSEA
analysis revealed that KIMAT1 KD led to suppression of genes
positively regulated by KRAS and enrichment of genes negatively
regulated by KRAS (Fig. 5e, f). KIMAT1 silencing reduced KRAS
endogenous levels as well as ERKs and AKT phosphorylation
and c-RAF level, supporting the existence of a positive feedback
loop (Supplementary Fig. 9b). Among the top enriched gene
signatures by GSEA upon DHX9 and NPM1 KD and in common
with KIMAT1 KD were those associated with KRAS, RAF and
MEK signaling (Fig. 5f). Randomly selected KRAS target genes
were further confirmed by qPCR analysis and immunoblotting
(Fig. 5g, h and, Supplementary Fig. 9c, d). In addition, Gene
ontology (GO) analysis identified pathways involved in cell
motility, cell-cell adhesion and angiogenesis, consistent with the
role of DHX9 and NPM1 in tumor progression (Supplementary
Fig. 9e). EMT gene signature was enriched in KIMAT1, DHX9
and NPM1 KD gene sets (Supplementary Fig. 10a) and selected
EMT genes were further confirmed by qPCR and immuno-
fluorescence (IF) (Supplementary Fig. 10b–d). In accordance with
a role in EMT, cells stably overexpressing KIMAT1 displayed an
elongated phenotype compared to parental cells (Supplementary
Fig. 10e). In summary, KIMAT1 controls oncogenic pathways,
including the KRAS pathway, at least in part, through DHX9
and NPM1.
KIMAT1 regulates the processing of oncogenic miRNAs
through DHX9 and NPM1. Seeking to define the mechanism
through which KIMAT1 could regulate KRAS expression and
global downstream signaling, we noticed that DHX9 had pre-
viously been reported to play a role in miRNA biogenesis by
interacting with DDX5 (p68) in the MC9,22. Because KIMAT1
stabilizes DHX9, we hypothesized that it might play a role in
miRNA processing and therefore regulate gene expression post-
transcriptionally. To test this hypothesis, we profiled miRNA
expression of KIMAT1 KD compared to control cells by next-
generation sequencing (NGS). Hierarchical clustering analysis
identified differentially expressed miRNAs, with 113 miRNAs
upregulated and 78 downregulated (Padj < 0.05) (Fig. 6a) (raw
data accessible via GSE124631). A majority of the upregulated
miRNAs upon KIMAT1 KD turned out to have tumor suppressor
properties whereas most of the downregulated miRNAs have
been previously reported to have oncogenic roles29,30. For
instance, the upregulated miR-200 family members, miR-27a,
miR-27b and let-7b upon KIMAT1 KD are well-known TS
miRNAs which play a crucial role in suppressing EMT in many
cancer types, including lung tumors31–35. On the contrary, among
the downregulated miRNAs upon KIMAT1 loss, miR-17-5p and
miR18a, as well as miR-375 and miR-10b have been previously
shown to be involved in lung cancer progression36–39. Interest-
ingly, network analysis revealed that genes belonging to pathways
activated by KIMAT1, including the KRAS pathway, were pre-
dicted targets of the KIMAT1-suppressed miRNAs (Supplemen-
tary Fig. 11a and Supplementary Data 4). To exclude that the
change in miRNA expression upon KIMAT1 KD was due to a
transcriptional effect we examined the expression of mature,
precursor and primary forms of selected KIMAT1-modulated
miRNAs. While mature and precursor miRNAs were affected by
KIMAT1 loss, the expression of primary miRNAs remained
unchanged, implying that KIMAT1-mediated miRNA regulation
occurs post-transcriptionally (Fig. 6b). In support of this
hypothesis, KIMAT1 KD promoted Drosha-mediated pri-miR-
27b in vitro processing, performed by incubating radio-labeled
pri-miR-27b with immunoprecipitated Drosha from H1299 cells
(Fig. 6c). Notably, DHX9 KO mimicked KIMAT1 KD, while
DHX9 OE sorted the opposite effect (Supplementary Fig. 11b),
suggesting that KIMAT1 effects on miRNA biogenesis are
mediated by DHX9.
To rule out a role for NPM1 in miRNA processing, we
analyzed the expression of the KIMAT1-modulated miRNAs in
NPM1 KO cells or after enforced expression of NPM1.
Unexpectedly, we observed a change at the precursor and mature
level while the primary remained unaffected, indicating that, as
with DHX9, NPM1 participates in miRNA processing (Supple-
mentary Fig. 11c). Since NPM1 is essentially a nuclear protein we
first tested whether NPM1 could interact with members of the
MC and detected a binding between NPM1 and DDX5 and
between DHX9 and NPM1 (Fig. 6d). To substantiate this, we also
transfected H1299 cells with a FLAG-tagged DHX9 expression
vector and carried out immunoprecipitation. Antibodies against
the FLAG epitope precipitated DHX9 along with NPM1 (Fig. 6e),
Fig. 2 KIMAT1 originates from TEs and is transcriptionally activated by MYC. a Cap analysis of gene expression-sequencing (CAGE-seq), from lung and
gastric cancer cells revealed the presence of a putative active promoter in KIMAT1 loci. CAGE-seq counts were defined by the FANTOM5 mammalian
promoter expression atlas in the IA-LM and H1299 lung adenocarcinoma and MKN45 gastric cancer cell lines at the KIMAT1 loci. b In-house and University
of California, Santa Cruz (UCSC) Genome Browser ChIP-seq data illustrating the recruitment of MYC to the KIMAT1 loci. Co-localization of H3K4me3 and
H3K27ac at the TSS in A549 cells (brown) was integrated with H3K4me3 and H3K27ac in-house ChIP-seq data (red). MYC-binding sites (BS) are
indicated by arrows. c, Schematic representation of KIMAT1 genomic locus composed by remnants of ERV1 and L1 DNA and enlargement of the MER-101-1
LTR containing two MYC BSs (in red). d Dual-luciferase assay in H1299 and CALU6 cells, showing that the MER101-1 LTR has promoter function as
compared to control (Empty vector). MYC silencing reduced luciferase activity, while deletion of the two MYC BSs in the MER101-1 rescued this effect. A
non-promoter region (NP) was used as negative control. **4.12E−05 in H1299 and **3.75E−08 in CALU6. e ChIP-qPCR in H1299 cells showing MYC or
IgG enrichment (ChIP/input) in the KIMAT1 promoter region (MER-101-1). TFAP4 was used as positive control. *0.001694, **3E−05. f Expression of
KIMAT1 in H1299 cells transfected with control siRNA (siCtrl) or MYC siRNA (siMYC). TFAP4 was used as positive control. siMYC vs siCtrl, KIMAT1
*0.018211 and siMYC vs siCtrl, TFAP4 *0.001253. gMYC KD suppressed the induction of KIMAT1 by wild type or mutant KRAS. Error bars indicate mean ±
S.D, n= 3 replicates. p values were calculated by two tailed Student’s t test.
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Fig. 3 KIMAT1 is an oncogenic lncRNA in NSCLC. a Confocal microscopy images of KIMAT1 smFISH (Red) in different cell lines. Images are representative
of two biological replicates. Nuclei were stained with DAPI (Blue). Scale bar, 75 μm. b qRT-PCR analysis for KIMAT1 following cytoplasmic (cyto) and
nuclear (nuc) fractionation of cell lysates, n= 3. c Cell proliferation assay upon transfection with two different KIMAT1 GpRs, n= 4. GpR-KIMAT1#3 vs Ctrl
**1.14E−09; GpR-KIMAT1#1 vs Ctrl **1.66E−07. d 3D invasion assay of H1299 cells transfected with two different KIMAT1 GpRs and quantification of the
tumorsphere area invading the matrigel, n= 4. GpR-KIMAT1#1 vs Ctrl **0.000601 and GpR-KIMAT1#3 vs Ctrl **0.000713 (H1299); GpR-KIMAT1#1 vs
Ctrl *0.026964 and GpR-KIMAT1#3 vs Ctrl *0.033348 (CALU1). Scale bar, 500 μm. e Quantification of Annexin V staining upon GpRs transfection in
multiple cell lines, n= 3. *0.013189 and *0.031027 (H1299); **7.99E−05 and *0.020508 (CALU1). f 3D invasion assay of H1299-KIMAT1 and H460-
KIMAT1 stable cells and quantification of the tumorsphere area invading the matrigel. KIMAT1 antisense was used as control. n= 4 (H1299) and n= 3
(H460). KIMAT1 OE vs EV *0.022 (H1299); KIMAT1 OE vs EV *0.002105 (H460). Scale bar, 500 μm. g, h Tumor growth curves of xenograft mouse
models derived from cell lines with stable overexpression of KIMAT1 (n= 8) compared to control mice (n= 8). Data show mean ± S.D. p values were
calculated by two tailed Student’s t test.
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confirming that NPM1 is part of a complex composed by DHX9
and DDX5. The association of DHX9 and NPM1 with DDX5 was
abrogated by treatment with RNase A, indicating that RNA
molecules, including KIMAT1, may be important for the binding
of DHX9 and NPM1 to the MC (Fig. 6f). However, we still
detected a binding between DHX9 and NPM1 in presence of
RNAse A. Thus, DHX9 and NPM1 interact in the nucleus
independently of KIMAT1 (Fig. 6f). Subsequently, to determine
whether DHX9 and NPM1 were able to bind to specific pri-
miRNA substrates, we conducted a CLIP assay which confirmed
that DHX9 and NPM1 bind to pri-miR-17-5p and -18a and not to
pri-miR-200b, -200c, -7, -27a, -27b, -139 and -let-7b (Supplemen-
tary Fig. 11d). We also performed an in vivo cellular monitoring
assay of DHX9 and NPM1 function, as previously reported9. Two
different cell lines were transfected with a luciferase vector
carrying a segment of pri-let-27b, -let-7b, -17-5p and -18a between
the luciferase gene and the polyadenylation signal (Supplemen-
tary Fig. 11e). As consequence of DROSHA-mediated cleavage of
the pri-miRNA, the luciferase transcripts lose their polyadenyla-
tion tail, resulting in poor stability and decreased translation9. In
this cellular system the luciferase intensity is inversely correlated
to Drosha activity (Supplementary Fig. 11e). This experiment
revealed that DHX9 or NPM1 silencing caused an increase in the
luciferase activity of cells transfected with pri-miR-17-5p and pri-
miR-18a and not of cells transfected with pri-miR-27b or pri-let-














































































































































































































































Cas9 DHX9 KO1 DHX9 KO2 NPM1 KO2NPM1 KO1
Fig. 4 KIMAT1 directly interacts with DHX9 and NPM1. a Schematic representation of RAP-MS. RBP= RNA-binding protein. b KIMAT1 pull-down with
biotinylated antisense probes after UV crosslinking followed by immunoblotting analysis showing that DHX9 and NPM1 are direct KIMAT1 binding partners.
A sample treated with RNase A or pull-down of the housekeeping gene UBC were used as negative controls. c Immunoblotting showing DHX9 and NPM1
pull-down efficiency for the experiment in d. d KIMAT1 is enriched by CLIP assay using DHX9 or NPM1 specific antibodies. e, f DHX9 and NPM1 sequential
immunofluorescence (green) and KIMAT1 smFISH (Red) in different lung adenocarcinoma cell lines. Scale bar, 75 μm. g Schematic representation of
human KIMAT1, its antisense (AS) and various deletion constructs generated to detect DHX9 or NPM1 binding regions in KIMAT1 sequence. Fragment sizes
were confirmed by PCR (bottom panel), and binding of each fragment to DHX9 or NPM1 determined via pull-down of biotinylated-labeled RNA fragments
and immunoblotting (IB) (top panels) with the indicated antibodies. BR binding region; nt nucleotide. h RNA immunoprecipitation assay. H1299 cells
were transfected with FLAG-tagged full-length DHX9 (FL), or DHX9 without the two double-stranded RNA-binding domains (dsRBD Del) or Empty
vector (NT), crosslinked and subjected to immunoprecipitation using FLAG-specific antibody. (Top) DHX9-bound KIMAT1 was analyzed by qPCR.
(Bottom) Immunoblotting showing immunoprecipitation’s efficiency. i RNA immunoprecipitation assay. H1299 cells were transfected with FLAG-tagged
full-length NPM1 (FL), or NPM1 without the RNA-binding domain (DRBD Del) or Empty vector (NT), crosslinked and subjected to immunoprecipitation
with a FLAG-specific antibody. (Top) NPM1-bound KIMAT1 was analyzed by qPCR. (Bottom) Immunoblotting showing immunoprecipitation’s efficiency.
j Immunoblotting showing DHX9 KO and NPM1 KO in two different CRISPR/Cas9 clones. k 3D invasion assay and quantification of the spheroid area in the
two DHX9 and NPM1 CRISPR/Cas9 clones in j compared to control cells (Cas9 only). Scale bar, 500 μm. l immunoblotting showing downregulation of
DHX9 and NPM1 upon transfection of H1299 cells with two KIMAT1 GpRs. a, b, e, f, g Representative results or images of two biological replicates. Mean ±
S.D (n= 3). p values were calculated by two-tailed Student’s t test.
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(Supplementary Fig. 11f). As for KIMAT1, network analysis
evidenced that genes belonging to pathways activated by DHX9
or NPM1 were predicted targets of DHX9- and NPM1-
suppressed miRNAs (Fig. 6g and Supplementary Data 4).
Altogether, these data suggest that KIMAT1 enhances the
processing of a subset of miRNAs that foster lung cancer
progression via DHX9 and NPM1.
p21 is a component of the microprocessor complex. Having
assessed that KIMAT1 KD induced downregulation of miR-17-
5p, -18a, -375 and 10b-5p via DHX9 and NPM1, we sought to
address how KIMAT1 KD could lead to the induction of miR-200
family members, miR-7, -27a, -27b, -139 and let-7b, considered to
have TS function in lung cancer. TP53 has been shown to
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growth suppressive functions8,40. However, RNA-seq analysis
(Supplementary Fig. 9a) was carried out in H1299 cells, which are
TP53-null. Thus, we searched for other potential tumor sup-
pressor genes derepressed after KIMAT1 KD and confirmed a
significant MYC-dependent upregulation of CDKN1A (p21)
(Fig. 7a and Supplementary Fig. 12a–c)41. Interestingly, network
analysis evidenced that MYC is a target of several KIMAT1-
repressed miRNAs, pointing to a post-transcriptional regulation
of MYC by KIMAT1 (Supplementary Fig. 12d). p21 attracted our
attention because it regulates multiple tumor suppressor path-
ways in a p53-independent fashion42 and its expression is
reduced in late compared to early stage lung cancer, suggesting
that p21 may be downregulated in more aggressive tumors43.
Therefore, we investigated whether p21 could be responsible for
the induction of KIMAT1-repressed miRNAs. p21 KD induced
marked upregulation of oncogenic-like miRNAs and down-
regulation of miRNAs with growth suppressive function, whereas
p21 enforced expression caused the opposite effect (Fig. 7b).
Importantly, the levels of the precursor miRNAs changed while
the primary remained unaffected, further substantiating that p21
may be involved in miRNA biogenesis (Fig. 7b). Because KIMAT1
KD induces MYC downregulation, we were surprised not to see
an effect on pri-miR-17-5p and pri-miR-18a, members of the well-
known MYC-induced miR-17-92 cluster44 upon KIMAT1 silen-
cing. Strikingly, pri-miR-17-5p and pri-miR-18a remained unal-
tered in cells transfected with a MYC siRNA, suggesting that in
our system MYC does not transcriptionally regulate members of
this cluster (Supplementary Fig. 12e). We then tested whether p21
could directly interact with members of the MC. Reverse co-
immunoprecipitation revealed an interaction between endogen-
ous Drosha and p21 in H1299 (p53 null) and A549 (p53WT),
confirming that p21 is a Drosha interactor (Fig. 7c).
CLIP assay revealed that p21 binds to pri-miR-200b, -200c, -27b
and let-7b and not to pri-miR-17-5p, 18a, -375 and -10b
(Supplementary Fig. 12f). To further verify a role for p21 in
miRNA processing, we performed an in vivo cellular monitoring
assay. H1299 and H460 cell lines were transfected with a
luciferase vector carrying a segment of pri-27b, pri-let-7b, pri-
miR-17 and pri-miR-18a between the luciferase gene and
polyadenylation signal9. p21 silencing caused an increase in the
luciferase activity in cells transfected with pri-27b and let-7b but
not in cells transfected with miR-17 and miR-18a, while p21 OE
resulted in the opposite effect (Supplementary Fig. 12g). Thus,
p21 may enhance the processing of a subset of miRNAs with
tumor suppressor function. In a rescue experiment, p21 OE
reduced the binding between primary oncogenic miRNAs and
DHX9 and between primary oncogenic miRNAs and NPM1
(Fig. 7d). Moreover, overexpression of p21 in A549 or H1299 cells
hampered the binding between DDX5 and DHX9 and between
DDX5 and NPM1 (Fig. 7e). These results pointed to a possible
antagonistic effect between components of the MC for the
binding to pri-miRNAs and for triggering their cleavage by
Drosha. Investigating this antagonistic effect further, we noticed
that p21 OE decreased DDX5 and NPM1 protein but not mRNA
levels (Fig. 7f and Supplementary Fig. 12h). Thus, p21 OE impairs
the binding between DHX9 and DDX5 and between NPM1 and
DDX5 by reducing DDX5 and NPM1 expression levels post-
transcriptionally. Conversely, DHX9 KO and NPM1 KO
decreased MYC expression with consequent p21 upregulation,
suggesting that in absence of DHX9 and NPM1, p21 binds to
Drosha to promote the processing of TS miRNAs (Supplementary
Fig. 12i). Importantly, p21 is downregulated in LUAD and LUSC
lesions (Supplementary Fig. 13a). p21 silencing increased the
capacity of the cells to proliferate, whilst p21 OE induced
significant cell death (Supplementary Fig. 13b and Fig. 7g),
revealing that the substantial apoptosis observed upon KIMAT1
KD could mainly be mediated by p21. Notably, pro-apoptotic
genes induced by KIMAT1 KD (Supplementary Fig. 13c) were
also induced by p21 OE in two NSCLC cell lines (Supplementary
Fig. 13d). Treatment with the transcription inhibitor Actinomy-
cin D did not affect p21-induced cell death, further substantiating
that p21-mediated effect on apoptosis is post-transcriptional
(Supplementary Fig. 13e). Altogether, these findings indicate that
p21 promotes the processing of TS miRNAs and its OE induces
cell death by post-transcriptional modulation of gene expression.
KIMAT1 silencing halts tumor growth in a PDX mouse model
while its overexpression promotes lung cancer progression.
Having assessed a role for KIMAT1 in the regulation of KRAS
signaling, we evaluated the biological effects of KIMAT1 mod-
ulation in lung tumors. GpRs have recently been shown to be
effective in targeting RNA in vivo24,45. To test the therapeutic
potential of KIMAT1 targeting in vivo, we employed a patient-
derived xenograft (PDX) lung squamous cell carcinoma model
harboring 6 copies of KRASWT from a patient with lymph node
metastasis (Supplementary Fig. 14a). Intravenous injections of
KIMAT1 GpRs alone significantly inhibited tumor growth,
reduced KRAS and Ki67 protein levels and induced cell death
in vivo, as revealed by the increase in cleaved caspase 3 (Fig. 8a, b
and Supplementary Fig. 14b). Importantly, tumors treated with
KIMAT1 GpRs showed remarkable downregulation of KIMAT1,
DHX9 and NPM1 and increased expression of p21 (Supple-
mentary Fig. 14c). Furthermore, to assess the metastatic potential
of cells overexpressing KIMAT1, we injected H1299 cells with
stable expression of KIMAT1 in the tail vein of NSG mice, as
previously described46,47. 17 weeks later metastases and micro-
metastases were observed in the lungs and liver of the majority of
mice injected with KIMAT1 stable cells compared to controls
(Supplementary Fig. 15a). We also performed orthotopic injec-
tions of H1299/luc2+/KIMAT1 and H460/luc2+/KIMAT1 stable
cell lines in the lungs of NSG mice and evaluated the capacity of
the cells to metastasise over time48,49. KIMAT1 OE promoted
Fig. 5 KIMAT1, DHX9 and NPM1 regulate the KRAS signaling. a, b DHX9 and NPM1 are overexpressed in LUAD lesions (n= 75) at different stage
(T1–T4) compared to matched normal lung samples and directly correlate with KRAS expression in the same samples. p values were calculated by two-
tailed Student’s t test. c Kaplan–Meier survival curves comparing survival of patients with high KIMAT1/DHX9/NPM1 expression (red line) to patients with
low KIMAT1/DHX9/NPM1 expression (blue line) from the TCGA LUAD dataset. The log rank p values were obtained from a two-tailed Chi-Square test.
d Venn diagram depiction of the overlap of significant differentially expressed genes between KIMAT1 and its interacting proteins and between DHX9 and
NPM1. e Enrichment plots of gene sets positively or negatively regulated by KRAS upon KIMAT1 KD. f Gene signature analysis of KIMAT1-, DHX9- and
NPM1-related pathways in KIMAT1 KD, DHX9 KD and NPM1 KD cells. Highlighted in red are the common signatures between KIMAT1, DHX9 and NPM1. p
< 0.05 by two sided Kolmogrorov–Smirnov (K-S) test. The resulting p values were corrected for multiple hypothesis testing. g, h Bar plot depiction of
the expression levels of randomly selected genes belonging to the KRAS signaling commonly modulated by KIMAT1, DHX9 and NPM1 by qRT-PCR. g (Left)
p values from left to right= 2.88E−05, 0.001022, 0.000675, 0.000367, 0.0008, 0.002051, 0.0001, 0.0168; g (Right) p values from left to right=
0.000316, 0.001236, 2.23E−05, 0.002561, 6.74E−05, 2.27E−05, 0.000226, 0.000531. h p values from left to right *0.0119, 0.003881, 0.00756,
0.007485, 0.0022, 0.0064, 0.0092, 0.014. Error bars represent mean ± S.D (n= 3). p values were calculated by two-tailed Student’s t test.
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tumor initiation and gave rise to malignant ascites and metastases
in liver and kidneys (Fig. 8c, d and Supplementary Fig. 15b–d).
Reciprocally, DHX9 KO and NPM1 KO reduced KRAS expres-
sion and the number of distant metastases in vivo (Fig. 8e and
Supplementary Fig. 16a–c). In a rescue in vivo experiment,
ortothopic injection of cancer cells simultaneously overexpressing
KIMAT1 and harboring DHX9 or NPM1 deletion (DHX9 KO or
NPM1 KO) halted KIMAT1-mediated metastatic effects, sug-
gesting that DHX9 and NPM1 are important mediators of
KIMAT1 function (Supplementary Fig. 17a–d).
Discussion
In this study, we have shown that KRASWT amplification is a
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is able to activate in vitro the same oncogenic pathways as mutant
KRAS, fostering cell migration and invasion and therefore, lung
cancer progression. LncRNAs are important regulators of gene
expression involved in several processes, spanning from tran-
scriptional to post-transcriptional regulation, mRNA splicing and
decay3,4. Here, we leveraged the pleiotropic functions of lncRNAs
to identify KRAS-regulated pathways that could be exploited for
therapeutic purpose. We characterized the top induced lncRNA
upon KRAS OE, KIMAT1, and demonstrated that it correlates
with KRAS expression in vitro and in vivo. Notably, high levels of
KIMAT1 and KRAS were observed in cells derived from meta-
static sites and in late stage lung adenocarcinomas. Consistent
with the hypothesis that KRAS amplification propels tumor
propagation, our experiments revealed that MYC, a well-known
KRAS-activated transcription factor fundamental for KRAS-
induced tumorigenesis18, binds to KIMAT1 promoter determin-
ing its activation. Inspection of the KIMAT1 locus evidenced that
it is essentially composed of TEs, and MYC-dependent tran-
scription of KIMAT1 is driven by a LTR originated from evolu-
tionary ERV1 integration events in the human genome. KIMAT1
silencing reduced 3D cell invasion and induced substantial pro-
grammed cell death in cancer and not in normal cells, suggesting
that it is essential for cancer survival. Although KIMAT1
expression is lower in cells with a mutational KRAS status
compared to those with amplified KRAS, the biological effects
upon KIMAT1 manipulation in these cells are similar to those
observed in cells with KRAS amplification. Furthermore, by RAP-
MS and CLIP assay we discovered that KIMAT1 binds to and
stabilizes DHX9 and NPM1, which are present in both the
nucleus and cytoplasm22,50, in accordance with KIMAT1 locali-
zation. DHX9 is overexpressed in many cancers but it is also
fundamental in maintaining normal cellular homeostasis22.
NPM1 is regarded as an effective therapeutic target for the
treatment of both solid and hematologic malignancies. Never-
theless, none of the molecules targeting NPM1 discovered in the
last few years have shown chemical features suitable for their
development as drugs51,52. KIMAT1 is detectable in cancer and
has very little or no expression in normal tissues. Thus, targeting
KIMAT1 would allow DHX9 and NPM1 silencing only in tumors,
without toxicity for the normal counterpart. MiRNAs are
important regulators of gene expression in physiological and
pathological processes, including cancer7,53. They can function as
both tumor suppressors and oncogenes depending on the cellular
context54,55. Our findings raise the possibility that KRAS is a
upstream regulator of the MC complex and regulates its own
signaling at least in part post-transcriptionally by governing
miRNA processing. KIMAT1, through DHX9 and
NPM1 stabilization and MYC-dependent suppression of p21,
promotes the processing of a subset of oncogenic-like miRNAs
while simultaneously halting the biogenesis of a subset of miR-
NAs with tumor suppressor function, maintaining a positive
feedback loop that potentiates the KRAS signaling (Fig. 8h). To
our knowledge, this antagonistic effect on miRNA processing by
members of the MC to promote or suppress tumorigenesis has
hitherto never been reported. Further investigation would be
fundamental in defining the effective number of pri-miRNAs that
bind to DHX9/NPM1 or p21 and how the recognition occurs.
Notably, previous studies reported that components of the MC
complex are maintained together by RNA molecules8; however,
none of these RNAs have so far been identified. Here, we
demonstrated that KIMAT1 is fundamental for the binding of
DHX9 and NPM1 to DDX5 and is therefore essential for miRNA
processing. In summary, we reported a so far unidentified net-
work downstream of KRAS that could be exploited for ther-
apeutic intervention to halt the adaptability of KRAS-driven
tumors. Given the recent promising results with RNA
therapeutics56, the important role of KIMAT1 in lung tumor-
igenesis and the robust effect in suppressing the growth of a
patient-derived tumor harboring KRASWT amplification, we put
forward the idea that its targeting may be effective in the treat-
ment of a subset of lung cancer patients for whom, at the
moment, there are no effective treatment options.
Methods
Murine models. Animal experimental procedures were approved by Cancer
Research UK Manchester Institute’s Animal Welfare and Ethical Review body in
accordance with the Animals Scientific Procedures Act 1986 and according to the
ARRIVE guidelines and the Committee of the National Cancer Research Institute
guidelines. All the in vivo studies, except the PDX mouse model, which was carried
out by Xentech (Evry, France), were conducted under the project license number
P72E31537 (M.G.). The PDX used was not generated for the purpose of this study.
The authorization (PDX mouse model) to use animals in the Center for Exporation
and Experimental Functional Research (CERFE, Evry, France) facility was obtained
by The “Direction of the Veterinarian Services, Ministry of Agriculture and Food,
France” (agreement No. D-91-228-107). All experiments are performed in accor-
dance with French legislation concerning the protection of laboratory animals and
in accordance with a currently valid license for experiments on vertebrate animals,
issued by the French Ministry of Higher Education, Research and Innovation.
Pascal Leuraud is in charge of the implementation and compliance to the Projects
Agreements: «Evaluation de l’activité antitumorale de candidats médicaments en
monothérapie sur des modèles de xénogreffes de tumeurs dérivées de patients»;
APAFIS#14073-2018021311396396 v2 (valid for 2 years from September 09th
2018). Mice were observed for signs of illness or distress during the course of the
experiments and body weight was measured twice a week. Animals were eutha-
nized after the appearance of predefined criteria like rapid weight loss (>20%) or
weight gain (>20% due to ascites) and labored respiration. After euthanasia mice
were analyzed for the presence of peritoneal tumors. Lungs, liver and kidneys were
excised, weighed, photographed and bisected. Part of the organs was fixed in
Fig. 6 KIMAT1 regulates miRNA processing. a Hierarchical clustering analysis of dysregulated miRNAs upon KIMAT1 KD. A padj ≤0.05 defined genes
significantly differentially expressed. Log2fold change (FC) > 0.48, <−0.27. Dysregulated miRNAs were obtained using the DESeq2 method, which utilizes
Negative Binomial GLM fitting and two-sided Wald test to compare two groups for hypothesis testing. The p values from the Wald test were corrected for
multiple testing using the Benjamini and Hochberg method. b Expression levels of mature, precursors and primary miRNAs with tumor suppressor (left) or
oncogenic function (right) in KIMAT1 KD cells by qRT-PCR. Primary and precursor miRNAs were normalized to β-actin, mature miRNAs were normalized to
RNU48. Error bars represent mean ± S.D (n= 3). **p value < 0.001, *p value < 0.05 by two-tailed Student’s t test. c KIMAT1 silencing induces Drosha-
mediated pri-miR-27b in vitro processing. n= 2. Pre-miR-27b band size= 97 nt. d Reverse IP demonstrating the interaction between DDX5 and NPM1 and
between NPM1 and DHX9 endogenous levels. Representative images of 2 biological replicates. e DHX9/NPM1 interaction following transfection of H1299
cells with a DHX9-Flag plasmid and subsequent immunoprecipitation using a Flag-specific antibody. Representative images of 2 biological replicates.
f Treatment with RNase A abrogates DHX9/DDX5 and DHX9/NPM1 interaction but not the interaction between DHX9 and NPM1. Representative images
of 2 biological replicates. g Directed Network Diagram of Enriched Pathways regulated by DHX9 and NPM1 with Predicted miRNA Targets derived from
each KD experiment (DEGs with FDR < 0.05 which are also predicted to be miRNA targets by Targetscan [release 7.2 – default predictions]). The
statistical method to obtain the DEGs has been described in the legend of Fig. 6a. The diagram displays miRNAs (blue squares) and pathways enriched
(orange circles) (FDR < 0.05; calculated using GSEA with the DEGs from DHX9/NPM1 KD) and the connecting edges (purple-dashed: DHX9; green-solid:
NPM1); edge-widths represent the number of DEGs contributing to the connection within each gene set. The network graph was produced using the igraph
package (version 1.2.4.2).
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formalin and subjected to immunohistochemistry (IHC) for further analysis. IHC
quantification was determined by QuPath (v0.0.0-m2). The remaining organ was
snap-frozen in liquid nitrogen and stored at −80 oC. RNA was isolated from tissues
with TRIzol solution and qPCR was performed to analyze genes and miRNA
expression.
Murine subcutaneous in vivo model. 5 × 106 H1299 and H460 cells stably
expressing a control vector (Ev) or KIMAT1 were subcutaneously injected into the
right posterior dorsal flank of 4–6 weeks old female NOD/SCID Gamma (NSG)
mice (n= 8 per group) (Charles River). All animals were maintained in a
pathogen-free environment with free access to food and water. Tumor size was
assessed twice per week using a digital caliper by measuring the length (l) and the
width (w) and calculated based on the formula V= lw2/2. Mice were euthanized
and sacrificed when tumor size reached the endpoint of 1500 mm3 or mice pre-
sented signs of illness.
Patient-Derived Xenograft (PDX) mouse model. Female NSG mice, weighting
20–30 g, 4–6 weeks old were maintained in specific pathogen-free animal housing.
The patient-derived xenograft (IC11LC13), from a patient with a lung squamous
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was transplanted subcutaneously onto mice. When tumors reached around 150
mm3, the tumor-bearing mice were randomly divided into equivalent groups of
7 animals. Mice were treated with 20 mg/kg of GpR KIMAT1 (n= 7) or vehicle
(n= 7), i.v. three times per week (the first two weeks) and then twice a week (the
last two weeks) for a total of 10 injections. All mice were weighted twice weekly.
Tumor growth was monitored by measuring tumor diameters with a caliper.
Tumor volume (V) was calculated as follows: V= a2 × b/2, where a is the width
(large diameter) and b the length (small diameter) of the tumor in millimeters. Two
tailed Student’s t test was used to measure statistical significance.
Mouse model of metastasis. 5 × 105 H1299/KIMAT1 or H1299/Empty vector
(H1299-Ev) cells in 0.2 ml PBS were injected in the tail vein of NSG mice (n= 7).
Seventeen weeks later, mice were sacrificed and lungs and livers were collected for
further analysis.
Orthotopic mouse model. NSG mice were anesthetized with isofluorane and
placed in the right lateral decubitus position. 2.5 × 106 H1299 or H460 cells stably
expressing KIMAT1 or a control vector (Ev) and the luciferase gene (luc2+), or
H1299 DHX9 KO, NPM1 KO cells using the CRISPR/Cas9 editing system were
injected with a 0.5 ml insulin syringe percutaneously into the left lateral thorax, at
the lateral dorsal axillary line of 5–7 weeks old NSG mice (8 mice per group). After
injection mice were transferred to a clean recovery cage on top of a heated mat and
observed until they fully recovered. Primary tumors and/or metastases were
examined over time using luminescence imaging (IVIS). Mice were sacrificed
5 weeks after the injection of the cells. Lungs, livers and kidneys were collected after
autopsy for histological analysis. Bioluminescent signal was quantified using IVIS
Spectrum in vivo Imaging System. Two tailed Student’s t test was used to measure
statistical significance.
Cell lines. Lung adenocarcinoma cell lines H1299, H460, A549, H1975, CALU1
and CALU6, lung squamous cell carcinoma cell line H520, lung fibroblasts
HEL299, lung bronchial epithelial cell line HBEC3-KT, normal human bronchial
epithelium BEAS2B cells, kidney embryonic cells HEK293 were purchased from
American Type Culture Collection (ATCC) and cultured as suggested by ATCC’s
guidelines. CORL-23 cells were purchased from Sigma-Aldrich. Type II pneumo-
cytes cells were a kind gift of Prof. Julian Downward (The Institute of Cancer
Research, London).
Human tissue samples. LUAD (HLugA150CS02) and LUSC (HLugSqu150SC01)
microarrays (TMA) were purchased from US biomax. Single-molecule RNA FISH
(smFISH) and IHC were used to examine the expression of KIMAT1, KRAS,
DHX9 and NPM1 in 75 tumor and matched normal lung samples (LUAD normal
n= 75, T1= 37, T2a= 14, T2b= 4, T3= 16, T4= 4; LUSC normal n= 75, T1=
23, T2a= 13, T2b= 10, T3= 24, T4= 5). Images were acquired with gSTED
microscope and spots were counted using the online JAVA software of
StarSearch57.
Cell fractionation. Total nuclear and cytoplasmic extracts were obtained from cells
cultured in 60-cm dishes using the Cytoplasmic and Nuclear RNA Purification Kit
(Norgen), according to the manufacturer’s instructions.
CPAT (Coding Potential Assessment). Coding potential for KIMAT1 was
determined using the CPAT tool16. KRAS and MALAT-1 were used as controls.
RACE. KIMAT1 5’ and 3’ ends were identified by Rapid amplification of cDNA
ends (RACE) using the Roche 5’/3’ Kit according to manufacturer’s instructions.
Briefly, RNA was extracted from H1299 cells and cDNA was synthesized using a
GSP1 primer or oligo (dT)-Anchor primer. RACE PCRs were amplified using High
Fidelity polymerase and separated on a 1% agarose gel. Gel purified products were
cloned in a pCDH vector and sequenced to identify the 5’ and 3’ ends of the
transcript. Primers are listed in Supplementary Table 3.
Gene editing via CRISPR/Cas9 system. Single guide RNA (sgRNA) sequences
targeting different segments of DHX9 genes were designed using the CRISPR
design tool (http://tools.genome-engineering.org)58. sgRNAs were inserted in a
GFP plasmid containing the Cas9 and the sgRNA scaffold (pSpCas9(BB)2A-GFP)
(addgene) digested with BbsI (ThermoFisher Scientific). The inserted sequences
were verified by sequencing. H1299 cells were transfected with the CRISPR/Cas9
constructs using Lipofectamine 2000 regent for 48 h and sorted based on GFP
expression using Flow Cytometry (Novocyte NovoExpress Software, version 1.3.0).
Primers are listed in Supplementary Table 3.
LncRNA cloning and lentiviral transduction. KIMAT1 full-length or deletion
constructs were PCR amplified and inserted into a lentiviral vector (pCDH-GFP,
System Biosciences). The inserted sequences were validated by sequencing. Cells
were sorted based on GFP expression using Flow Cytometry (Novocyte NovoEx-
press Software, version 1.3.0). Primers are listed in Supplementary Table 3.
Dual-Luciferase reporter assay. Two LTRs upstream of KIMAT1 TSS containing
two and one MYC BS respectively, were PCR amplified and inserted into a pro-
moterless pGL3 basic vector (Promega). 200 ng of pGL3 basic vector, 20 ng of
Renilla plasmid (Promega), and 50 nM of MYC siRNA (Applied Biosystems) were
co-transfected in H1299 or CALU6 cells for 48 h. Dual-Luciferase Assay (Promega)
was used to examine luciferase activity. Primers are listed in Supplementary
Table 3. Deletion of MYC-binding sites was obtained using the QuickChange
Mutagenesis Kit (Stratagene).
In vivo monitoring of pri-miRNA processing. The firefly luciferase pmirGLO
Plasmid (Promega) containing pri-miRNA sequences (primiR-27b, let-7b, miR-17,
miR-18a) at the 3’ untranslated region, a Renilla plasmid and DHX9/
NPM1 siRNAs or DHX9/NPM1 expression vectors were co-transfected into H1299
or H460 cells for 48 h. Dual-Luciferase Assay (Promega) was performed to examine
the reporter activity. Primers are listed in Supplementary Table 3.
In vitro pri-miRNA processing. In vitro pri-miRNA processing assay was per-
formed as previously described59. Pri-miR-27b containing the stem-loop sequence
plus 150 flanking bp was PCR amplified with a T7 containing forward primer and
purified PCR product in vitro transcribed in the presence of α32P CTP (Perki-
nElmer). 105 cpm isotope-labeled pri-miRNA was incubated at 37 °C for 90 min
with a reaction containing 30 μl of Drosha IP complex, 3 μl of 10× reaction buffer
(64 mM MgCl2), 0.75 μl of RNase inhibitor (Roche) in RNase free water. RNA was
extracted with phenol/chloroform and precipitated with ethanol overnight. RNA
was loaded on a 6% denaturing polyacrylamide gel and then exposed with XAR-5
autoradiography film (KODAK) overnight at −80 °C with an intensifying screen.
Pri-miRNA cloning primers are listed in Supplementary Table 3.
Protein extraction and immunoblotting. Total protein lysates were homogenized in
1× RIPA buffer (Sigma-Aldrich) plus protease inhibitors (Roche) and centrifuged with
Fig. 7 p21 is a component of the MC and antagonizes DHX9 and NPM1 effect on miRNA biogenesis. a KIMAT1 KD induces MYC downregulation and p21
upregulation. Representative images of 2 biological replicates. b Expression levels of primary, precursors and mature forms of the indicated miRNAs were
analyzed by qPCR after silencing or overexpression of p21 in H1299 cells. Primary and precursor miRNAs were normalized to β-actin and mature miRNAs
were normalized to RNU48. sip21 vs siCtrl pre-miRNA and mature miRNA p value= 0.013 (pre-miR-7), 0.003 (miR-7-5p), 0.001 (pre-miR-27a), 0.018
(miR-27a-3p), 0.0496 (pre-miR-27b), 0.008 (miR-27b-5p), 0.00015 (pre-miR-139), 0.008 (miR-139-5p), 0.004 (pre-let-7b), 0.0011 (let-7b-3p), 0.011
(pre-miR-17), 0.0024 (miR-17), 0.0004 (pre-miR-18a), 0.001 (miR-18a), 3.448E-05 (pre-miR-375), 0.0015 (miR-375), 0.001 (pre-miR-10b), 0.0014
(miR-10b-5p); p21 OE vs Ev pre-miRNA and mature miRNA p value= 0.002 (pre-miR-7), 0.001 (miR-7-5p), 1.06E-06 (pre-miR-27a), 0.0002 (miR-27a-
3p), 0.0014 (pre-miR-27b), 0.007 (miR-27b-5p), 7.9E-05 (pre-miR-139), 0.002 (miR-139-5p), 0.002 (pre-let-7b), 0.0001 (let-7b-3p), 0.0019 (pre-miR-
17), 0.0001 (miR-17), 0.0009 (pre-miR-18a), 0.003 (miR-18a), 0.03 (pre-miR-375), 0.002 (miR-375), 0.005 (pre-miR-10b), 0.0007 (miR-10b-5p). c p21
interacts with Drosha in p53 null and p53 wild-type cells. Representative images of 2 biological replicates. d CLIP analysis of the association between the
indicated primary miRNAs and DHX9 or NPM1 upon p21 OE. Cells were transfected with p21 and immunoprecipitated with anti-DHX9 or anti-NPM1
antibody. Pri-miR-17-5p/miR-18a/miR-375/miR-10b expression was analyzed by qRT-PCR. UBC was used as a negative control. Error bars represent mean ±
S.D (n= 3), **p value < 0.001, *p value < 0.05 by a two-tailed Student’s t test. (Left) From left to right p values= 0.0013436, 0.001265, 0.0004582,
0.002409, 0.000873, 0.014035, 7.022E−05, 0.001565; (Right) From left to right p values= 0.0013656, 0.013152, 0.0321765, 0.029651, 0.0043712,
6.92E−05, 0.0088363, 0.000348. e p21 OE abrogates the interaction between DHX9 and DDX5 and between NPM1 and DDX5. Representative images of
2 biological replicates. f p21 enforced expression reduces DDX5 and NPM1 protein level. Representative images of 2 biological replicates. g p21 OE in p53
null or wild-type cells induces prominent cell death.
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13,000 × g for 20min at 4 oC. Protein concentration was measured by SpectraMax M5
(SoftMax Pro6) using the Pierce BCA Assay Kit (ThermoFisher Scientific). Super-
natant was used for immunoblotting with the indicated antibodies. Signal was detected
using Western Bright ECL-Spray substrate and ChemiDoc instrument (Bio-Rad).
RNA extraction and quantitative real-time PCR (qRT-PCR). Total RNA was
isolated from cells and tissues using TRIzol according to the manufacturer’s
instructions. For miRNA detection, 50 ng of RNA was reverse-transcribed using
TaqmanTM miRNA Reverse Transcription Kit and miRNA specific probes
(Applied BiosystemsTM). For gene detection, cDNA was synthesized from 1 μg of
total RNA using Verso cDNA Synthesis Kit (ThermoFisher Scientific), and real-
time PCR was performed using SYBR Green PCR master mix (Applied Biosys-
temsTM). Relative miRNA or gene expression was calculated using ΔCT normal-
ized to RNU48 or β-actin, respectively. Primer sequences are listed in
Supplementary Table 4. RNA integrity was verified on an Agilent Bioanalyzer 2100
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Chromatin immunoprecipitation (ChIP). ChIP assay was performed as previously
described60. Online databases Encode and UCSC genome browser were used to
visualize the H3K4me3, H3K27ac and MYC ChIP-seq signals in KIMAT1 pro-
moter. Primers and antibodies are listed in Supplementary Table 4 and Supple-
mentary Table 5.
siRNA, LNATM GapmeR and plasmid transfection. Commercially available ON-
TARGET plus smart pools siRNA for EGFR, MYC, CDKN1A and NPM1 were
purchased from Dharmacon and their sequences are listed in Supplementary
Table 1. siRNA for DHX9, KRAS were purchased from Thermofisher Scientific.
Three different LNATM GpRs for KIMAT1 were designed and synthesized from
Qiagen. GapmeRs (50 nM) and siRNAs (50 nM) were transfected using Hiperfect
reagent (Qiagen) for 48 h according to the manufacturer’s instructions. Plasmids
were transiently transfected into the cells with Lipofectamine 2000 reagent
(ThermoFisher Scientific). H1299 or H460 cells were transfected with a pGL4-luc2
(Promega) construct to stably express the luciferase gene, selected using 100 μg/mL
of Neomycin (Sigma-Aldrich) and pooled for in vivo experiments. siRNA, GpR
sequences and plasmids are listed in Supplementary Table 1 and Supplementary
Table 6.
Transcriptome analysis. RNA-seq reads were quality checked with FastQC
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and aligned in
paired-end mode to the human genome assembly (GRCh37) using the RSubread
package aligner61 with the default settings. Mapped data were converted to gene
level integer read counts using feature Counts (RSubread package) and the
Ensemble GTF annotation (Homo_sapiens.GRCh37.74). Expression of a gene was
measured in RPKM (Reads Per Kilobase Million) units.
Differentially expressed gene (DEG) analysis. Differential expression (DE) was
evaluated comparing the gene level integer read count data for the knockdown and
control samples using the DESeq2 Bioconductor package62 with default settings. A
gene was considered differentially expressed if its abundance changed more than
1.5-fold between the two conditions. The resulting p values were adjusted (padj)
using the Benjamini and Hochberg approach for controlling the false discovery rate
(FDR). Genes with an adjusted p value determined to be <0.05 (FDR < 0.05) by
DESeq2 with a fold change value ≥1.5 or ≤0.8 between two groups were considered
to be differentially expressed.
Network analysis. The integrative analysis was performed using data from
KIMAT1 KD or DHX9/NPM1 KD RNA-seq to find shared enriched pathways
within the sets of differentially expressed (DE) genes which are predicted targets of
a pre-defined set of miRNAs. GSEA was performed and a consensus set of path-
ways were developed into a network diagram. Predicted miRNA targets for the set
of miRNAs were acquired from the Targetscan database (release 7.2). Predicted
targets which were DE within each siRNA experiment were subject to GSEA using
the Hallmark and C6 Oncogenic gene sets (MSigDB version 7); this was performed
using the GSEA_r package (version 1.2) within the R environment (version 3.6.1).
Gene sets (pathways) which reached significance (FDR < 0.05) were compared
between the experiments and a set was chosen to produce a network graph. The
network graph displays miRNAs (blue squares) and pathways (orange circles) and
the connections between them (purpledashed: DHX9; green-solid: NPM1; gray
solid: KIMAT1); edge-weights represent the number of DEGs contributing to the
connection within each gene set. The network was produced using the igraph R
package (version 1.2.4.2).
MiRNA sequencing. Small RNA-seq raw reads from control and treated (KIMAT1
KD) samples were quality checked using FastQC (https://www.bioinformatics.
babraham.ac.uk/projects/fastqc/). The FASTX-Toolkit (http://hannonlab.cshl.edu/
fastx_toolkit/) was used to trim 3’ small RNA-seq adapter sequence. Reads smaller
than 18 nt were discarded. The cleaned reads for each sample along with the
human reference genome (hg19), all the known human hairpins and human
mature miRNA sequences from miRBase database (Release 21) were used as input
in mirDeep2 to quantify miRNA abundances. The raw miRNA counts form
mirDeep2 were used in DESeq262 to identify differentially expressed miRNAs
between control and treated samples at a FDR threshold of ≤0.05.
Identification of lung cancer-associated protein-coding genes and lncRNAs.
Differentially gene expression datasets were compiled by the Molecular Biology
Core Facility Team (MBCF) at Cancer Research UK Manchester Institute. The
Cancer Genome Atlas (TCGA), Lung Adenocarcinoma (LUAD) and Lung Squa-
mous Cell Carcinoma (LUSC) alignment files (BAM) were downloaded from
dbGap and processed to generate raw expression files. We extracted gene expres-
sion matrices specifically for cancer patients which were composed of 542 and
502 samples respectively. Differential expression between these cancer patients
against 427 normal lung samples taken from Genotype-Tissue Expression (GTex)
(version 7) was performed. Only genes that were present and had a minimum
count of 11 across all samples in their respective comparisons were considered for
differential expression analysis. R Bioconductor package DESeq2 (v1.26.0) was
used and a gene was considered differentially expressed if it passed a false discovery
rate threshold of 5%. Scatterplots were generated using the overlapped differentially
expressed genes between NGS experiments and TCGA/GTex.
Expression of KIMAT1 in TCGA, GTEx and cell lines from CCLE. TCGA data for
a total of 10,480 tumors across 33 cancer types were acquired from the Cancer
Genomics Cloud. Gene counts for GTEX samples (n= 11,688) were downloaded
from https://gtexportal.org/home/. The raw read counts were first converted to
RPKM values and then transformed to log2 scale. A pseudo-count of 1 was added
to avoid taking log of zero. Samples on x axis are ordered by the average expression
of the lncRNAs. KIMAT1 expression data were obtained from the file CCLE_R-
NAseq_081117.rpkm.gct downloaded from CCLE data portal (http://portals.
broadinstitute.org/ccle/data). Cell lines of interest were grouped by their respective
tissue types. The expression data, in the form of RPKM values, were converted to
log2 scale and a pseudo-count of 1 was added to avoid taking log of zero. A total of
863 cell lines across 19 tissue types were analyzed.
CCLE and TCGA KRAS copy number. Raw Affymetrix CEL files were converted
to a single value for each probe set representing a SNP allele or a copy number
probe. Copy numbers were then inferred based upon estimating probe set specific
linear calibration curves, followed by normalization by the most similar HapMap
normal samples. Segmentation of normalized log2 ratios (specifically, log2 (CN/2))
was performed using the circular binary segmentation (CBS) algorithm. TCGA
copy number annotation: Copy number values: −2= homozygous deletion; −1=
hemizygous deletion; 0= neutral/no change; 1= gain; 2 or more= high level
amplification.
Overall survival analysis. Disease free survival and overall survival (OS) analysis
were performed on LUAD and LUSC datasets considering KRAS amplification plus
mutation. Kaplan–Meier curves are generated at 2.5 years, 5 years and 20
years follow-up period using samples for which both survival and expression data
were available. BAM files for all these datasets were downloaded from GDC
(https://portal.gdc.cancer.gov/) and counts were extracted from the BAM files
using feature Counts.
Gene Ontology (GO) and gene set enrichment analysis (GSEA). Gene ontology
and gene set enrichment analysis were performed to investigate whether the dif-
ferentially expressed genes (DEGs) were part of specific pathways. The GO func-
tional annotation was explored with BINGO. Gene signature Analysis was based on
MSigDB v6.2 database using the GSEA desktop implementation software63. Genes
Fig. 8 KIMAT1 silencing halts tumor growth in vivo while its OE promotes tumorigenesis and distant metastases. a Tumor volume of IC11LC13 PDX
mice treated by intravenous injections with vehicle (Ctrl) or GpR-KIMAT1 (Error bars represent mean ± S.D, p value by a two-tailed Student’s t test.). Ctrl
n= 6, KIMAT1 KD n= 3. *0.01194 and 0.002246. b Representative IHC images of KRAS and Ki67 levels in lungs of mice treated with KIMAT1 GpRs
compared to controls. c Representative lungs and livers from NSG mice percutaneously injected into the left lateral thorax with H1299luc+ cells stably
expressing KIMAT1 or an empty vector. Tumors are evidenced by dashed lines. n= 7. d Representative examples of H&E staining of livers, kidneys and
lungs from mice injected with KIMAT1 stable cells as in c. A single isolated tumor cell is present (arrow head) in the liver of a H1299/Ev mouse. No
neoplastic cell is present in a H1299/Ev mouse kidney, whereas a small neoplastic lesion is observed within its lung (under the dashed line). Mice injected
with H1299/KIMAT1 cells presented diffuse metastatic infiltration in the livers, peri-renal fat tissue (under the dashed line) and the lungs (mostly entirely
substituted by neoplastic tissue). Original magnifications 0.6× and 40×; scale bar, 50 μm. n= 7. e Representative H&E and KRAS staining of lung sections
from NSG mice percutaneously injected with DHX9 KO or NPM1 KO cells. Original magnifications 0.6× and 40×; scale bar, 50 μm. n= 8. f Schematics
depicting KIMAT1’s mechanism of action. KRAS amplification activates KIMAT1 via MYC-mediated transcription. KIMAT1 binds to and stabilizes DHX9 and
NPM1, which promote the processing of oncogenic miRNAs sustaining the KRAS signalling in a positive feedback loop. p21 antagonizes the binding
between DDX5 and DHX9 and between DDX5 and NPM1 fostering the processing of tumor suppressor miRNAs which halt KRAS signalling and EMT.
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in the dataset were pre-ranked and weighted by the independent gene-level Wald
statistics and 1000 phenotype-based permutations were conducted. To understand
the functions of KIMAT1 regulated genes GSEA was performed using the
HALLMARK and C6 oncogenic signatures and a gene log2-fold change. Significant
terms with p values less than 0.05 were considered significant.
Cross-linked RNA Immunoprecipitation (CLIP). CLIP was performed as pre-
viously described64. Cells were UV irradiated at 0.8 J/cm2, lysed in RIPA buffer
(Sigma-Aldrich) with 1× protease inhibitor cocktail (Sigma-Aldrich) and RNase
inhibitor (NEB) for 10 min in ice. Lysates were then precleared with Protein G
beads (Thermofisher Scientific) for 1 h at 4 oC, and immunoprecipitated with IgG
or the indicated antibodies for 3 h at 4 oC. Immuno-complexes were precipitated
with Protein G beads and washed six times with washing buffer (50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 1 mM MgCl2, and 0.05% IGEPAL CA-630). 10% of beads
were boiled with 1× Laemli buffer (Bio-Rad) at 95 °C for 5 min and loaded on a
polyacrylamide gel to verify immunoprecipitation efficiency. The remaining
beads were treated with TurboDNase (Thermofisher Scientific) and Proteinase
K (NEB) and RNA was isolated using the TRIzol solution. UBC was used as a
negative control.
Native RNA pull-down assay. DNA of KIMAT1 full length or deletion constructs
were amplified by PCR. T7 RNA polymerase promoter sequences were added to
forward primers for subsequent in vitro transcription. PCR products were purified
with Gel Extraction Kit (Qiagen) and transcribed in vitro using Biotin RNA
labeling Mix Kit (Roche) and T7 RNA Transcription Polymerase (Roche)
according to the manufacture’s instruction. 3 μg of Biotin-labeled lncRNA (full-
length or fragments) were diluted into 40 μl RNA structure buffer (10 mM Tris-
HCl pH7.0, 10 mM MgCl2, 0.1 M KCl), heated at 90 °C for 2 min and placed in ice
for additional 2 min. Samples were kept at room temperature for 30 min to gen-
erate RNA secondary structures. Meanwhile, 80% confluent cells were washed with
cold PBS and collected. After centrifugation, cells were re-suspended in 1 ml chilled
RIP buffer (25 mM Tris-HCl pH7.4, 150 mM KCl, 5 mM EDTA, 0.5% NP40) and
sheared using a Bioruptor device with 30 strokes of 30 s on and 45 s off. 2 mg of
sheared lysates were added to the folded RNA in RIP buffer supplemented with a
final concentration of 0.1 μg/μl tRNA at 4 °C for 2 h. Pre-washed streptavidin beads
were mixed with RNA-cell lysate complex and further incubated for 1 h at 4 °C.
Beads were washed six times and boiled in 1× Laemmli loading buffer (Bio-Rad).
Retrieved protein samples were examined using immunoblotting.
Co-immunoprecipitation (Co-IP). 5.0 × 107 cells were washed with pre-chilled
PBS and re-suspended in 400 μl RIPA buffer (Sigma-Aldrich) plus protease inhi-
bitors (Sigma-Aldrich). Pre-cleared lysates were immunoprecipitated with the
indicated antibodies for 3 h at 4 °C. Next, the immunocomplex was incubated with
Protein G beads overnight at 4 °C, washed six times with washing buffer (50 mM
Tris-HCl pH 7.5, 150 mM NaCl, 1 mMMgCl2, and 0.05% IGEPAL CA-630), boiled
with Laemli buffer (Bio-Rad) at 95 °C for 5 min and analyzed by immunoblotting.
Ubiquitination assay. H1299 cell were transfected with GpRs Ctrl or GpRs
KIMAT1 for 48 h and treated with MG132 (20 μM) for 4 h. Then, cells were
harvested and lysates incubated with DHX9 or NPM1 antibody plus Protein G
beads overnight at 4 °C. The precipitated complex was boiled in 1× Laemli buffer at
95° and the supernatant was used for immunoblotting with an ubiquitin antibody.
KIMAT1 transcript boundaries. KIMAT1 transcription starting site (TSS) was
identified using CAGE-seq counts data obtained from gastric and lung adeno-
carcinoma cell lines from the FANTOM5 study (https://fantom.gsc.riken.jp/5/).
JASPAR was used to predict the likelihood of transcription factors binding sites in
KIMAT1 sequence.
Cell viability and IncuCyte cell growth analysis. 5.0 × 103 cells were cultured in
96-well plates. Cell viability was assessed using the CellTiter 96 Aqueous One
Solution Cell Viability assay (Promega) and measured at 490 nm as per manu-
facturer’s instructions in a Multilabel Counter (SpectraMax M5). Cell Confluence
was analyzed using the IncuCyte Zoom live-cell imaging systems from Essen
Bioscience. Cells seeded into a 96-well plate were transfected with 50 nM of
GapmeRs using Lipofectamine RNAiMAX. Phase-contrast images were then taken
every two hours for a total of 72 h and the percentage of confluence was calculated
with the Incucyte Zoom software.
Caspase-Glo 3/7 and Annexin V assay. 5.0 × 103 cells were seeded in 96-well
plates for 48 h. Caspase-3/7 activity was measured by adding 100 μl of Caspase-Glo
3/7 solution (Biorad) for 30 min at room temperature in the dark. For the Annexin
V assay, cells were grown in 6-well plates, transfected with GpRs for 48 h and then
washed with cold PBS and harvested with trypsin. Cell pellets were incubated with
Annexin V for 15 min (Trevigen) in the dark at room temperature. 400 μl 1×
binding buffer was then added to the cells and the percentage of apoptotic cells
analyzed using Flow Cytometry (NovoCyte NovoExpress Software version 1.3.0).
Colony formation assay and cell count. 5.0 × 103 cells were seeded in six-well
plates. 2 weeks later cells were washed with PBS and fixed with cold methanol,
stained with 0.05% crystal violet (Sigma-Aldrich), photographed and counted using
the GelCount System (Oxford Optronix) and the GelCountTM operating software.
3D proliferation assay. 2.0 × 103 cells either transfected with KIMAT1 GpRs or
DHX9 and NPM1 siRNAs, DHX9 KO and NPM1 KO cells or with stable over-
expression of KIMAT1, were cultured on ultra-low attachment plates (ULA,
Corning) and incubated at 37 °C for 10–15 days. Tumorsphere area was analyzed
using Image J software.
3D invasion assay. 2.0 × 103 cells in 200 μl RPMI-1640 were placed in ULA plates
and incubated at 37 °C for 7 days. Next, 100 μl of medium was gently removed and
100 μl of RPMI-1640 medium containing 3.8 μg/ml of Matrigel (Corning) was
added into the wells. Cells were kept at 37 °C for 7 more days. Area of the
tumorspheres was quantified with Image J software.
Single-molecule fluorescence in situ hybridization (smFISH). To detect
KIMAT1 at the single cell level a pool of 27 custom Stellaris FISH probes were
designed using the online tool (https://www.biosearchtech.com) to sequentially
cover KIMAT1 RNA sequence. To avoid off-target hybridization, BLAST was used
to remove unspecific probes. Probes were labeled with CAL Fluor Red 590 or
Quasar 570 dye and synthesized by LGC Biosearch Technologies. Cells were grown
on a coverslip for 48 h and fixed with 4% formamide at room temperature for
10 min, washed with PBS and permeablized with 70% ethanol for one hour at 4 oC.
Then, cells were incubated in the dark with the hybridization buffer (LGC Bior-
esearch Technologies) containing the probes (125 nM) at 37 °C for at least 4 h and
counterstained with DAPI (5 ng/ml) at 37 °C for 30 min. Images were acquired
with gSTED microscope and spots were counted using the online JAVA software of
StarSearch57. FISH probes are listed in Supplementary Table 2.
RNA antisense purification and mass spectrometry. RAP-MS was performed as
previously described21. To pull down endogenous KIMAT1, 5’ biotinylated 20-mer
antisense oligonucleotides were designed using the online tool (https://www.
biosearchtech.com) and synthesized by LGC Biosearch Technologies. Cells (2.0 ×
108 cells per sample) were UV cross-linked and lysed in 2 ml RIPA buffer (Sig-
maAldrich). Cell lysates were sonicated using a Bioruptor shearing device. Pre-
cleared cell lysates were mixed with 20 μg of lncRNA antisense probes and
incubated for 2 h at 67 °C with intermittent mixing at 1100 × g on a thermomixer.
Washed beads were added to the lysate-probes complex and further incubated for 2
h at 67 °C. Beads were washed six times and boiled in 1 x Laemli loading buffer
(Bio-Rad). Protein lysates were loaded on a SDS-PAGE gel (Bio-Rad) and protein
bands were destained in 1 ml of 100mM ammonium bicarbonate, 40% methanol at
37oC. Gel bands were then washed in 1ml of HPLC grade water for 10min before
removal of the water. Gel pieces were dehydrated by the addition of 1 ml acetonitrile
for 10min followed by the removal of the acetonitrile. The water-acetonitrile
hydration-dehydration cycle was repeated a total of 3 times. Dehydrated gel pieces
were then rehydrated in 100 μl of 40mM ammonium bicarbonate, 10% acetonitrile
carrying 12.5 ng/μl sequencing grade trypsin for 20min before the removal of any
excess. Gel pieces were then covered with 100 μl of 40mM ammonium bicarbonate,
10% acetonitrile and incubated at 37 °C for 16 h. Digests were acidified by the
addition of trifluoroacetic acid to a final concentration of 0.1% before removal of the
digest from the gel with subsequent drying of the sample in a vacuum centrifuge.
Dried peptide samples were then resuspended in 2% acetonitrile, 0.05% tri-
fluoroacetic acid prior to injection on the nano LC system Peptides were injected
directly onto a 25 cm long 75 μm ID, 2 μm C18 pepmap EasySpray column
(Thermo) using an RSLCn HPLC system (Thermo) at a flow rate of 200 nl/min.
Peptides were separated with a gradient of 1–22% acetonitrile 0.1% formic acid over
30 min at a temperature of 60 oC. The EasySpray column interfaced directly into an
Orbitrap Fusion mass spectrometer with a spray voltage of 1.4KV. The instrument
was operated in data-dependent mode with a 120,000 resolution orbitrap MS1 scan
over a mass range of 350–1000m/z with a target value of 2E5 ions and a maximum
fill time of 50 ms. MS2 HCD spectra were collected in the linear ion trap with a 3 m/
z isolation window, 28% normalized collision energy, rapid scan rate with a target
value of 1e4 ions and a maximum fill time of 50ms. Raw data was processed using
Mascot Distiller (Matrix Science) to generate MGF peak lists which were subse-
quently submitted to a Mascot (Matrix science) database search. Mascot search
results were then imported in Scaffold 4 (Proteome software). Two independent
biological replicates were analyzed and to minimize the potential background two
separate samples, as negative control, were incubated either with the housekeeping
gene Ubiquitin C (UBC) or treated with RNase (10 ug/ml at 37 °C for 30min) prior
the hybridization step. 5’ biotinylated 20-mer antisense oligonucleotides are listed in
Supplementary Table 2. The mass spectrometry data have been deposited to the
ProteomeXchange Consortium via the PRIDE65 partner repository with the dataset
identifier PXD024388 and 10.6019/PXD024388”.
Sequential immunofluorescence and FISH assay. Cells were grown on coverslips
for 48 h and fixed with 4% PFA at room temperature for 10 min, permeablized with
0.2% Triton X-100/PBS for 5 min at room temperature. Coverslips were then
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incubated with anti-DHX9 or anti-NPM1 primary antibodies and Alexa Fluor 488-
conjugated secondary antibodies and re-fixed with 4% PFA. smFISH was per-
formed as previously described. Digital photographs were acquired with a Two-
Photon Excitation gSTED Microscope (Leica) and visualized in Leica Advanced
Fluorescence software (Leica).
Statistics and reproducibility. Error bars in all the plots indicate mean ± S.D.
p value < 0.05 was considered statistically significant. **p value < 0.001, *p value <
0.05 by two tailed Student’s t test. All experiments were performed at least three
times unless otherwise indicated. Statistics was calculated with Excel 2010 or
GraphPad Prism 8.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
RNA-seq and ChIP-seq data generated in this study have been deposited in the Gene
Expression Omnibus database under the accession code: GSE124631. The mass
spectrometry data have been deposited to the ProteomeXchange Consortium via the
PRIDE partner repository with the dataset identifier PXD024388 and https://doi.org/
10.6019/PXD024388”. A list of proteins interacting with KIMAT1 by mass spectrometry
is provided in Supplementary Data 3. Publicly available ChIP-seq data are available from
ENCODE (https://www.encodeproject.org). Some of the data/analyses presented in the
current publication are based on the use of study data downloaded from the dbGaP web
site, under phs000178.v11.p8/ https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.
cgi?study_id=phs000178.v11.p8. Source data are available as a Source Data file. The
remaining data are available within the Article, Supplementary Information or available
from the authors upon request. Source data are provided with this paper.
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